Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tecovirimat - SIGA Technologies

Drug Profile

Tecovirimat - SIGA Technologies

Alternative Names: Arestvyr; SIGA-246; ST-246 Form I (monohydrate); ST-246 Form V (hemihydrate); ST-246®; Tecovirimat monohydrate - SIGA Technologies; TPOXX

Latest Information Update: 10 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ViroPharma
  • Developer Biomedical Advanced Research and Development Authority; SIGA Technologies
  • Class Antivirals; Benzamides; Indoles; Small molecules
  • Mechanism of Action Vaccinia virus p37 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Smallpox; Orthopoxvirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Smallpox
  • Phase I Orthopoxvirus infections

Most Recent Events

  • 03 Oct 2019 SIGA Technologies announces intention to submit NDA of intravenous tecovirimat to US FDA for Smallpox in 2020
  • 03 Jun 2019 Tecovirimat licensed to Meridian Medical Technologies for marketing worldwide except USA and South Korea
  • 30 Oct 2018 Launched for Smallpox in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top